Aleix Prat
Target (United States)(US)Breast Cancer Research Foundation(US)Cancer Institute (WIA)(IN)Departament de Salut(ES)Center for Cancer and Blood Disorders(US)Hospital Quirónsalud Barcelona(ES)Hospital Clínic de Barcelona(ES)Cancer Clinic(US)Institute for Research in Biomedicine(ES)Center for Cancers and Blood Disorders(US)Solti(ES)Colorado Blood Cancer Institute(US)Biomedical Research Institute(US)Oryzon Genomics (Spain)(ES)Spanish Ovarian Cancer Research Group(ES)Austrian Breast & Colorectal Cancer Study Group(AT)Fundació Clínic per a la Recerca Biomèdica(ES)Consorci Institut D'Investigacions Biomediques August Pi I Sunyer(ES)Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer(ES)Universitat de Barcelona(ES)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies, Cancer Treatment and Pharmacology, Cancer Genomics and Diagnostics
Most-Cited Works
- → Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer(2022)2,396 cited
- → Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer(2010)2,126 cited
- → Immune-related adverse events of checkpoint inhibitors(2020)1,326 cited
- → Deconstructing the molecular portraits of breast cancer(2010)1,323 cited
- → Clinical implications of the intrinsic molecular subtypes of breast cancer(2015)1,294 cited
- → 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)(2018)1,168 cited